Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular domain of glycoprotein NMB (GPNMB), which is overexpressed in certain human breast cancers and melanomas. This antibody can be conjugated with the cytotoxic drug monomethyl auristatin E to create glembatumumab vedotin, an antibody-drug conjugate (ADC) designed to deliver antitumor agents directly to cancer cells. Glembatumumab vedotin demonstrates significant antitumor activity by exploiting the specificity of the antibody to direct cytotoxic activity to GPNMB-expressing tumor cells, thereby minimizing systemic toxicity. This mechanism positions it as a promising therapeutic option in the treatment of GPNMB-expressing malignancies.
Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular domain of glycoprotein NMB (GPNMB), which is overexpressed in certain human breast cancers and melanomas. This antibody can be conjugated with the cytotoxic drug monomethyl auristatin E to create glembatumumab vedotin, an antibody-drug conjugate (ADC) designed to deliver antitumor agents directly to cancer cells. Glembatumumab vedotin demonstrates significant antitumor activity by exploiting the specificity of the antibody to direct cytotoxic activity to GPNMB-expressing tumor cells, thereby minimizing systemic toxicity. This mechanism positions it as a promising therapeutic option in the treatment of GPNMB-expressing malignancies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
